Africa - Australia - Barbados - Brazil - Canada - China - Egypt - Europe - Finland - Germany - High-income countries - Hong Kong - India - International - Italy - Japan - Mexico - Netherlands - Poland - Republic of Korea - Spain - Sweden - Thailand - United Kingdom - United States - West Africa - {Related topics}

Africa

• BMJ Open
  • Triple-negative breast cancer prevalence in Africa: a systematic review and meta-analysis [2022]

Australia

• Hereditary Cancer in Clinical Practice
  • Assessment of genetic referrals and outcomes for women with triple negative breast cancer in regional cancer centres in Australia [2021]

• Journal of Cancer Policy
  • The emerging burden of triple-negative breast cancer in Australia: Universal care does not guarantee equitable access [2026]

• SA Health
  • Capecitabine and Pembrolizumab (Triple Negative Breast Cancer)

Barbados

• Cancer
  • High triple-negative breast cancer prevalence and aggressive prognostic factors in Barbadian women with breast cancer [2020]

Brazil

• BMC Cancer
  • Management of early-stage triple-negative breast cancer: recommendations of a panel of experts from the Brazilian Society of Mastology [2022]

Canada

• Current Oncology
  • Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with Triple Negative Breast Cancer in Both the Early and Metastatic Setting 2025 [2026]
  • Canadian Expert Recommendations on Safety Overview and Toxicity Management Strategies for Sacituzumab Govitecan Based on Use in Metastatic Triple-Negative Breast Cancer [2024]

China

• Breast
  • Cost-effectiveness of sacituzumab tirumotecan versus chemotherapy for patients with metastatic triple-negative breast cancer in China [2025]

• Cancer Medicine
  • Cost-effectiveness analysis of tumor-infiltrating lymphocytes biomarkers guiding chemotherapy de-escalation in early triple-negative breast cancer [2023]

• Frontiers in Public Health
  • Toripalimab plus chemotherapy in the treatment of metastatic triple-negative breast cancer: a cost-effectiveness analysis [2024]

• PLoS ONE
  • Cost-effectiveness of sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer in China [2026]

Egypt

• Journal of Medical Economics
  • The cost-effectiveness of treatment for high-risk, early-stage, triple-negative breast cancer in Egypt: an analysis of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant single-agent pembrolizumab [2025]

Europe

• European Medicines Agency
  • The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer [2022]

Finland

• Breast Cancer Research and Treatment
  • FANCM mutation c.5791C>T is a risk factor for triple-negative breast cancer in the Finnish population [2017]

Germany

• BMC Cancer
  • Adherence to treatment guidelines and survival in triple-negative breast cancer: a retrospective multi-center cohort study with 9156 patients [2013]

• Geburtshilfe und Frauenheilkunde
  • Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) – Recommendations for Daily Routine Practice [2019]

High-income countries

• PharmacoEconomics
  • Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review [2022]

Hong Kong

• Hong Kong Medical Journal
  • Expert consensus recommendations on the daily clinical use of pembrolizumab for early triple-negative breast cancer [2025]

India

• JCO Global Oncology
  • Meta-Analysis of Prevalence of Triple-Negative Breast Cancer and Its Clinical Features at Incidence in Indian Patients With Breast Cancer [2020]

• South Asian Journal of Cancer
  • Practical consensus recommendations on management of triple-negative metastatic breast cancer [2018]

International

• American Society of Clinical Oncology Educational Book
  • Stage I Triple-Negative Breast Cancer: Moving From One-Size-Fits-All to a Personalized Approach [2026]

• Asian Journal of Surgery
  • Efficacy of breast conservative surgery versus modified radical mastectomy for triple-negative breast cancer: A systematic review and meta-analysis [2022]

• BJR|Artificial Intelligence
  • Radiologic imaging biomarkers in triple-negative breast cancer: a literature review about the role of artificial intelligence and the way forward [2024]

• Breast
  • A systematic review and meta-analysis of BRCA1/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer [2022]

• British Journal of Cancer
  • Reconsidering the definition of triple-negative breast cancer in the immune checkpoint inhibitor era: an optimal cut-off value for hormone receptor percentage of HER2-negative invasive breast cancer [2026]

• Cancer Treatment Reviews
  • Evolving therapeutics and ensuing cardiotoxicities in triple-negative breast cancer [2024]

• Cancers
  • Sacituzumab Govitecan in Triple Negative Breast Cancer: A Systematic Review of Clinical Trials [2024]
  • Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer [2021]

• Cell & Bioscience
  • Classifications of triple-negative breast cancer: insights and current therapeutic approaches [2025]

• Cochrane Database of Systematic Reviews
  • Platinum-based chemotherapy for early triple-negative breast cancer [2023]

• Critical Reviews in Oncology/Hematology
  • Benefit of adjuvant chemotherapy in patients with T1a-bN0, triple-negative breast cancer - A systematic review and meta-analysis [2026]
  • Reawakening the master switches in triple-negative breast cancer: A strategic blueprint for confronting metastasis and chemoresistance via microRNA-200/205: A systematic review [2024]

• European Journal of Nuclear Medicine and Molecular Imaging
  • The impact of PET imaging on triple negative breast cancer: an updated evidence-based perspective [2024]

• Expert Opinion on Biological Therapy
  • Developing combination therapies with biologics in triple-negative breast cancer [2024]

• Frontiers in Immunology
  • The efficacy and safety of sacituzumab govitecan in the treatment of breast cancer: a systemic review and meta-analysis of emerging clinical data [2025]

• Frontiers in Oncology
  • Efficacy and safety of taxanes combined with chemotherapy drugs in advanced triple negative breast cancer: A meta-analysis of 26 randomized controlled trials [2022]

• Histopathology
  • Real-world prevalence of PD-L1 positivity in early-stage/metastatic triple-negative breast cancer: primary results and pathology insights from the global retrospective observational VANESSA study [2026]

• ImmunoTargets and Therapy
  • Recent Advances in Immune Checkpoint Inhibitors for Triple-Negative Breast Cancer [2025]

• International Journal of Molecular Sciences
  • Non-Coding RNA-Based Therapeutic Strategies in Triple-Negative Breast Cancer: A Systematic Review [2026]
  • Triple-Negative Breast Cancer Unveiled: Bridging Science, Treatment Strategy, and Economic Aspects [2025]

• International Journal of Nanomedicine
  • Extracellular Vesicles as Emerging Drug Delivery Platforms in Triple-Negative Breast Cancer: A Systematic Review [2026]

• JNCI Cancer Spectrum
  • Treatment strategies for triple-negative primary breast cancer in older women: a systematic review [2025]

• Journal of Biomedical Science
  • Non-coding RNAs as modulators of radioresponse in triple-negative breast cancer: a systematic review [2024]

• Journal of Clinical Medicine
  • Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC) [2023]

• Journal of the National Cancer Institute
  • The unique risk factor profile of triple-negative breast cancer: a comprehensive meta-analysis [2024]

• Materials Today Bio
  • Research progress of paclitaxel nanodrug delivery system in the treatment of triple-negative breast cancer [2024]

• Medicine
  • Comparing efficacy of neoadjuvant therapy of triple-negative breast cancer: A Bayesian network meta-regression analysis [2026]

• Military Medical Research
  • Targeting RTKs/nRTKs as promising therapeutic strategies for the treatment of triple-negative breast cancer: evidence from clinical trials [2024]

• Technology in Cancer Research & Treatment
  • Targeting Receptor Tyrosine Kinases as a Novel Strategy for the Treatment of Triple-Negative Breast Cancer [2024]
  • Molecular Classification, Treatment, and Genetic Biomarkers in Triple-Negative Breast Cancer: A Review [2023]

• Translational Breast Cancer Research
  • Advances in antibody-drug conjugates in the treatment of advanced triple-negative breast cancer: a narrative review [2025]

Italy

• Cancer Treatment Reviews
  • Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review [2023]

• Cancers
  • Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM) [2019]

• Oncologist
  • Delphi consensus on the management of adverse events in patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan [2025]

Japan

• Breast
  • Comparison of neoadjuvant and adjuvant chemotherapy for operable triple-negative breast cancer before the era of immune checkpoint inhibitors: A retrospective study from the Japanese National Clinical Database-Breast Cancer Registry [2025]

Mexico

• Breast Cancer Research and Treatment
  • The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer [2015]

Netherlands

• Laboratory Investigation
  • Programmed Death Ligand-1 Testing in Triple-Negative Breast Cancer: National Practice and Interlaboratory Variation in the Netherlands [2026]

Poland

• Oncology in Clinical Practice
  • Systemic treatment in triple-negative breast cancer patients — standard and novel approaches [2024]

Republic of Korea

• PLoS ONE
  • Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean Population [2015]

Spain

• Targeted Oncology
  • Second-Line Treatment Options for Patients with Metastatic Triple-Negative Breast Cancer: A Review of the Clinical Evidence [2025]

Sweden

• Breast Cancer Research and Treatment
  • Worse survival despite indolent features for triple-negative invasive lobular carcinoma: a Swedish nationwide registry-based study [2025]

• Journal of Geriatric Oncology
  • Age and comorbidity in relation to treatment and survival outcomes in triple-negative breast cancer: A Swedish nationwide registry-based study [2025]

Thailand

• PLoS ONE
  • Real-life clinical pattern, management, and survival in Thai patients with early-stage or metastatic triple-negative breast cancer [2018]

United Kingdom

• National Institute for Health and Care Excellence
  • Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies [2022]
  • Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer [2022]
  • Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer [2022]
  • Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer [2020]

• Vaccines
  • Manufacturing and Financial Evaluation of Peptide-Based Neoantigen Cancer Vaccines for Triple-Negative Breast Cancer in the United Kingdom: Opportunities and Challenges [2025]

United States

• Advances in Therapy
  • Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States [2023]

• American Cancer Society
  • Treatment of Triple-negative Breast Cancer

• American Society of Clinical Oncology
  • Use of Immune Checkpoint Inhibitors in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A [2022]
  • Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update [2022]

• American Society of Clinical Oncology Educational Book
  • Early-Stage Triple-Negative Breast Cancer Journey: Beginning, End, and Everything in Between [2023]

• Annals of Surgical Oncology
  • Identifying and Treating Those at Risk: Disparities in Rapid Relapse Among TNBC Patients in the National Cancer Database [2024]

• Breast Cancer Research and Treatment
  • Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing [2014]

• Cancers
  • Present and Future of Immunotherapy for Triple-Negative Breast Cancer [2024]

• Frontiers in Oncology
  • Targeted therapy approaches for epithelial-mesenchymal transition in triple negative breast cancer [2024]

• Frontiers in Public Health
  • Racial and regional disparities of triple negative breast cancer incidence rates in the United States: An analysis of 2011-2019 NPCR and SEER incidence data [2022]

• JAMA Network Open
  • Trends and Disparities in the Use of Immunotherapy for Triple-Negative Breast Cancer in the US [2025]
  • Clinical and Demographic Factors, Treatment Patterns, and Overall Survival Associated With Rare Triple-Negative Breast Carcinomas in the US [2021]

• JCO Oncology Practice
  • Treatment Patterns, Trends, and Outcomes of Neoadjuvant Chemotherapy Use Among Patients With Early-Stage Invasive Triple-Negative Breast Cancer [2025]

• JNCCN
  • Integrating Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Practical Evidence-Based Considerations [2022]

• Journal of Clinical Pathways
  • Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer [2021]

• Oncologist
  • Clinical perspective on management of key adverse events with sacituzumab govitecan [2025]
  • Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities [2021]

• Pharmaceutics
  • Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook [2023]

West Africa

• JCO Global Oncology
  • Prevalence and Mortality of Triple-Negative Breast Cancer in West Africa: Biologic and Sociocultural Factors [2021]

{Related topics}

• Topic
  • Breast cancer